EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome - Test2 - elhamkhani - TriplyDB

EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

http://www.wikidata.org/entity/Q24655053

about

Testing women with endometrial cancer for lynch syndrome: should we test all?Era of universal testing of microsatellite instability in colorectal cancer Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer How do we approach the goal of identifying everybody with Lynch syndrome?PMS2 monoallelic mutation carriers: the known unknown Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness.Molecular pathogenesis of sporadic colorectal cancers Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer.Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through.Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives Universal molecular screening does not effectively detect Lynch syndrome in clinical practice Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2.Genetic testing for hereditary colorectal cancer.Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.Genetic testing for lynch syndrome in individuals newly diagnosed with colorectal cancer to reduce morbidity and mortality from colorectal cancer in their relatives Clinical relevance of microsatellite instability in colorectal cancer.Genetic predisposition to colorectal cancer: where we stand and future perspectives Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory.The mutational spectrum of Lynch syndrome in cyprus.The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.Application of molecular diagnostics for the detection of Lynch syndrome.Msh6 protects mature B cells from lymphoma by preserving genomic stability.Making sense of missense in Lynch syndrome: the clinical perspective Colorectal cancer in Chinese patients: current and emerging treatment options.Direct-to-patient disclosure of results of mismatch repair screening for Lynch syndrome via electronic personal health record: a feasibility study.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome.Knowledge, attitudes and referral patterns of lynch syndrome: a survey of clinicians in australia BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome The search for unaffected individuals with Lynch syndrome: do the ends justify the means?

P2860

Q24562824-1A519F37-AC3E-41FE-A046-01ACC69AF980 Q24596823-1EA14138-C9DF-4E90-AB14-30255E5A91D8 Q24611865-7CFF72A3-74F1-4EA7-A6A7-0D64273C29A4 Q26779546-D57911EE-2683-46E5-A69F-38FE285F5C4F Q26797255-0C7CBFF6-B790-4CA9-9AC4-45D419E55293 Q26865836-66EE3A75-B5BB-48A3-863A-F6E384E75953 Q27024662-14752107-04A1-4651-B5D0-2309709589F0 Q27324818-09AC9DB3-87ED-499B-AFB6-D69BC51FDA05 Q28078345-5D6882C0-AC5B-4577-B88F-36C32719498B Q28085485-457BE731-D218-426E-BB90-3E7524B2F3BB Q30275239-3213635F-DADC-46D7-8266-55C218C0C93D Q30275554-0BEF14BE-0890-44FC-AE1D-D8219C7A2AE1 Q30513982-1D27173B-36F4-47B7-8DE5-3E32ADB7EC5A Q30587310-55E9E97F-5562-411B-9546-5984AC620E1C Q31139897-8227DECF-2062-49F7-82B1-62978F224878 Q33605565-EFD9E8CF-43F8-4949-A487-669A7091053E Q33640008-4C9406D1-CEEE-4B60-9921-2529D9E01608 Q33649978-DD52D1ED-5BF9-4A9D-A3EC-5F0916B5D2E9 Q33711113-76330CB6-B207-4FC0-B16F-AEB57B0DFA0C Q33754229-BFE84292-BEAB-44AF-88C3-78AC9A4B77ED Q33775296-0910B3AE-7CB2-4E0E-B4DE-0386E37798AF Q33848817-B0A01713-1112-42E1-9ECB-C5E8C2B5B322 Q33874719-424D1227-0763-4057-9A46-EE7642B41BB0 Q33945376-35ADBE87-E96E-4E90-9F6F-9C4EC2267AA6 Q33956968-8D357C04-8010-441F-8BF5-9F5F4EFE0723 Q33990921-11380EB3-14D8-49C0-82C0-DC66E2E09275 Q34008801-940131B3-598A-415B-9CDA-F6A9CB8EB0C5 Q34022144-6B674506-A699-4A4D-A424-6980BEED88DB Q34062115-2DCACDDA-668A-4D0C-B04F-B2CB9DD7B187 Q34081267-C75F4AF1-5F5F-4014-8D74-C0467DBAF90A Q34088809-C6113CA2-6C72-4D7F-B2A4-F5A7F542E018 Q34254602-8AE7063B-A16A-4990-9AEB-B86F39E8CA9D Q34332422-4D5C5052-4EBB-47C7-82AF-7838E8BF128A Q34352595-F3B43413-2B97-4B73-83B0-E0BF5CC1D9F2 Q34437807-D40E7247-B497-4AFC-AFB2-78D175E191FF Q34441837-BE1B65C4-F9D7-4EC6-94A5-DE61F3DB147A Q34543387-8DD9FB9E-2169-4B3A-9FF6-E4A7E16821B9 Q34683932-2FCE46ED-C519-4C50-A608-117995155DED Q34782265-28C38521-3325-46E2-B9EB-7595C85D012F Q34792640-3C268A6D-C6CB-4607-87D0-36ABB766D7DA

P2860

EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

http://www.wikidata.org/entity/Q24655053

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@ast

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@en

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@nl

type

label

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@ast

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@en

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@nl

prefLabel

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@ast

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@en

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@nl

P1433

Q24655053-D7F6B096-D199-4E38-BE2F-DD9577D9C7B1

P1476

Q24655053-A5F6BB55-997B-4638-A66D-693CD64E4FDB

P2093

Q24655053-C6F7874F-2369-49C7-A2F5-C6E371AC8380

Q24655053-D8E7CB3F-16E3-421D-A509-322FB3E57CF5

Q24655053-DA7D6E8C-C67C-41B8-997E-E666B5D0A3EA

Q24655053-F992E524-32A4-4DA1-894E-FA7F638031FC

P2860

Q24655053-019FA5E2-F947-4D0D-AA15-DE89FA08A986

Q24655053-062E5830-9908-4A06-8D80-957DCD49B070

Q24655053-06E2A92C-B6DB-4714-9FBE-47F684FA3556

Q24655053-08D0E26C-F774-4987-9EFF-87D58CBAFB15

Q24655053-0ACD5583-A6FA-47D0-8009-117A56866283

Q24655053-0C813733-0E3A-4DED-B5F7-B810EDA63E48

Q24655053-0F89C675-4C31-421F-897B-D8FF833B29BD

Q24655053-107DD2F9-EFFC-4E7E-9632-0EC777AD2511

Q24655053-18246881-DDE7-4198-9FC6-432298F98C8F

Q24655053-1A1B1471-F7F3-4CE8-AEE5-4C0424D94371

P2888

Q24655053-74080477-6A31-42AC-8035-E39972CA3A2F

P304

Q24655053-B6989852-9A73-4F4B-9841-3C73B208DC8C

P31

Q24655053-00D95561-899D-4EDB-9747-AD816A6D2E75

P3181

Q24655053-E90C102D-52E1-4AD9-966C-0BC486835E26

P356

Q24655053-C1D861AD-AEA4-416C-BCDF-712E43725F11

P407

Q24655053-75B58232-DFE9-412E-A37B-B6EA40C314C7

P433

Q24655053-DB2E538E-C124-400D-A05F-80A6F6B4E8CE

P478

Q24655053-98D529F3-F04C-451E-984B-7FCFD1CC0FCB

P50

Q24655053-CF03921F-EC55-4B28-9BBB-75A43DF255FD

P577

Q24655053-4F97785C-5820-4933-B31F-51917A02784F

P6179

Q24655053-37137EC7-E8E0-4570-9938-3991868DAA70

P698

Q24655053-70224EA3-F08E-4264-BD8B-35996A901B0E

P932

Q24655053-E222ABA7-9E5E-4BC8-8A4C-B5A6CE5075A0

P3181

P356

GIM.0B013E31818FA2DB

P1433

Genetics in Medicine

P1476

EGAPP supplementary evidence r ...... mortality from Lynch syndrome

@en

P2093

Glenn E Palomaki

http://www.w3.org/2001/XMLSchema#string

Heather L Hampel

http://www.w3.org/2001/XMLSchema#string

Monica R McClain

http://www.w3.org/2001/XMLSchema#string

Stephen N Thibodeau

http://www.w3.org/2001/XMLSchema#string

P2860

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X

The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

Systematic review of microsatellite instability and colorectal cancer prognosis

Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines

Microsatellite analysis of hereditary nonpolyposis colorectal cancer-associated colorectal adenomas by laser-assisted microdissection: correlation with mismatch repair protein expression provides new insights in early steps of tumorigenesis

Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry.

Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term.

Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.

P2888

gim.0b013e31818fa2db

P304

42-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4352482

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/GIM.0B013E31818FA2DB

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Stephanie M. Melillo

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1004538373

http://www.w3.org/2001/XMLSchema#string

P698

19125127

http://www.w3.org/2001/XMLSchema#string

P932

2743613

http://www.w3.org/2001/XMLSchema#string